

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/11 C07K16/18

C12Q1/68 A61K48/00

A61K39/395 G01N33/53

A61K38/00 A61P35/00 A61K31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

MEDLINE, BIOSIS, EPO-Internal, PAJ, WPI Data, EMBASE, CHEM ABS Data

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
х	WO 95/28484 A (AMGEN INC) 26 October 1995 (1995-10-26)	28,29, 31,33, 34,36, 51,53
	page 11, line 9-12	1
	page 13, line 29-33	1
	figure 1]
	table 2	
	claims 1,31,33	
	-/	
	,	
		İ
		1
		{

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of ched documents: 'A' document defining the general state of the last which is not considered to be of perticular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is clied to establish the publication date of another clatton or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed	'T' tater document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention. 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an invention step when the document is taken alone. 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the ext. '&' document member of the same patent tamily
Date of the actual completion of the international search	Date of mailing of the international search report
28 June 2004	1 3 07 2004
Name and mamng address of the ISA European Palent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Riswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer Lechner, 0

Form PCT/ISA/210 (second sheet) (January 2004)

11


C (Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Calegory *		Relevant to claim No.
Υ .	ZOU JUNE X ET AL: "An Eph receptor regulates integrin activity through R-Ras" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 24, 23 November 1999 (1999-11-23), pages 13813-13818, XP002265365 Nov. 23, 1999 ISSN: 0027-8424 page 13818 -& KIYOKAWA ETSUKO ET AL: "Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors" CANCER RESEARCH ISSN: 0008-5472, vol. 54, no. 14, 1994, pages 3645-3650, XP001156923 abstract page 3647, right-hand column, line 3	1-4, 6-12,15, 28-31, 33-36, 51,53
Y	VOGT THOMAS ET AL: "Eph-receptor tyrosine kinase profiles of malignant melanomas at a glance: cDNA miniarray discloses expression profiles indicative for redundant autocrine loops" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03), page 788 XP001156950 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000 ISSN: 0197-016X abstract	1-4, 6-12,15, 28-31, 33-36, 51,53
Y	KATAOKA HIDEKI ET AL: "Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer" JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 128, no. 7, July 2002 (2002-07), pages 343-348, XP001156841 ISSN: 0171-5216 abstract page 344, left-hand column, paragraph I page 345, right-hand column, last paragraph page 347, right-hand column, paragraphs 3,4 -/	1-4, 6-12,15, 28-31, 33-36, 51,53
	;	

ational Application No PCT/EP 03/07399

		<u></u>
Calegory *	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Chation of document, with indication, where appropriate, of the relevant passages	· Relevant to claim No.
Calegory	Cuation of document. With indication, where appropriate, or the relevant passages	Appears to California.
Y	HOLDER NIGEL ET AL: "Eph receptors and ephrins: Effectors of morphogenesis" DEVELOPMENT (CAMBRIDGE), vol. 126, no. 10, May 1999 (1999-05), pages 2033-2044, XP001156919 ISSN: 0950-1991 abstract page 2039, left-hand column, paragraph 3 -right-hand column, paragraph 1	1-4, 6-12,15, 28-31, 33-36, 51,53
Α	OVING IRMA M ET AL: "Molecular causes of colon cancer." EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. ENGLAND JUN 2002, vol. 32, no. 6, June 2002 (2002-06), pages 448-457, XP002265366 ISSN: 0014-2972 the whole document	1-4, 6-12,15, 28-31, 33-36, 51,53
A	HERZIG M ET AL: "Recent advances in cancer research: mouse models of tumorigenesis" BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1602, no. 2, 21 June 2002 (2002-06-21), pages 97-113, XP004356804 ISSN: 0304-419X page 100, left-hand column, last paragraph -right-hand column, paragraph 1	1-4, 6-12,15, 28-31, 33-36, 51,53
Α	MARIADASON J M ET AL: "Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation." CANCER RESEARCH. UNITED STATES 15 APR 2001, vol. 61, no. 8, 15 April 2001 (2001-04-15), pages 3465-3471, XP002223972 ISSN: 0008-5472 the whole document	1-4, 6-12,15, 28-31, 33-36, 51,53
А	NAISHIRO Y ET AL: "Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation." CANCER RESEARCH. UNITED STATES 15 MAR 2001, vol. 61, no. 6, 15 March 2001 (2001-03-15), pages 2751-2758, XP002223973 ISSN: 0008-5472 the whole document	1-4, 6-12,15, 28-31, 33-36, 51,53
	-/	

national Application No PCT/EP 03/07399

HARADA N ET AL: "Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 1 JAN 2001, vol. 91, no. 1, 1 January 2001 (2001-01-01), pages 67-75, XP002223971 ISSN: 0020-7136 -& WIELENGA-VJ ET AL.: "Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway" AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 2, February 1999 (1999-02), page 515-23 XP002224014 WO 01/98350 A (CHIRON CORP) 27 December 2001 (2001-12-27) 1-4,6-9, 27-31, 33-36, 42,48,51 abstract claims 1-23	C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells." INTERNATIONAL DUCNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 1 JAN 2001, vol. 91, no. 1, 1 January 2001 (2001-01-01), pages 67-75, XP002223971 ISSN: 0020-7136 -& WITLENGA-VJ ET AL.: "Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway" AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 2, February 1999 (1999-02), page 515-23 XP002224014 WO 01/98350 A (CHIRON CORP) 27 December 2001 (2001-12-27) A WO 00/70076 A (HUMAN GENOME SCIENCES INC claims 1-23 WO 00/70076 A (HUMAN GENOME SCIENCES INC ;NI JIAN (US); ROSEN CRAIG A (US); FAN P) 11,12, 23 November 2000 (2000-11-23) abstract paragraph '0004!; table 1 page 82-84 page 106 page 138 page 153, last paragraph page 165, line 16,17	Calegory *	Castlon of document, with Indication, where appropriate, of the relevant passages	· Relevant to claim No.
27 December 2001 (2001-12-27) 15,21, 27-31, 33-36, 42,48,51 WO 00/70076 A (HUMAN GENOME SCIENCES INC; NI JIAN (US); ROSEN CRAIG A (US); FAN P) 23 November 2000 (2000-11-23) abstract paragraph '0004!; table 1 page 82-84 page 106 page 138 page 153, last paragraph page 165, line 16,17	A	antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 1 JAN 2001, vol. 91, no. 1, 1 January 2001 (2001-01-01), pages 67-75, XP002223971 ISSN: 0020-7136 -& WIELENGA-VJ ET AL.: "Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway" AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 2, February 1999 (1999-02).	
Claims 1-23 WO 00/70076 A (HUMAN GENOME SCIENCES INC; NI JIAN (US); ROSEN CRAIG A (US); FAN P) 23 November 2000 (2000-11-23) abstract paragraph '0004!; table 1 page 82-84 page 106 page 138 page 153, last paragraph page 165, line 16,17	X	27 December 2001 (2001-12-27)	15,21, 27-31, 33-36,
;NI JIAN (US); ROSEN CRAIG A (US); FAN P) 23 November 2000 (2000-11-23) 11,12, 15,20, 26, 28-31, 33-36, 41,47,51 abstract paragraph '0004!; table 1 page 82-84 page 106 page 138 page 153, last paragraph page 165, line 16,17			
abstract paragraph '0004!; table 1 page 82-84 page 106 page 138 page 153, last paragraph page 165, line 16,17	A	;NI JIAN (US); ROSEN CRAIG A (US); FAN P)	11,12, 15,20, 26, 28-31, 33-36,
-/		paragraph '0004!; table 1 page 82-84 page 106 page 138 page 153, last paragraph	
		 -/	
	m PCT/ISA	10 (communition of account sheet) (January 2004)	



C.(Continue Category *	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Challon of document, with Indication, where appropriate, of the relevant passages	Helevant to claim No.
χ		
	WO 02/051438 A (MAX PLANCK GESELLSCHAFT; STAHL BERND (DE); MACCHI PAOLO (DE); BONH) 4 July 2002 (2002-07-04)	1-4,6-9, 15,20, 26, 28-31, 33-36, 41,47,51
	abstract page 5, paragraph 2 page 6, paragraphs 1,3 page 9, paragraph 4 page 10, paragraphs 1,2 page 11, paragraph 2 page 13, paragraphs 2-4 page 14, paragraphs 1,4,5 page 15, paragraph 2 page 16, paragraph 3 page 17, paragraph 4 page 19, paragraphs 2,3	
X	WO DO/73801 A (OBATA YUICHI ;LUDWIG INST CANCER RES (US)) 7 December 2000 (2000-12-07)	1-9,15, 20,26, 28-36, 41,47,51
	abstract page 6, line 17-27 page 11, line 21-31 page 12, line 12-17 page 23, paragraphs 8-32 page 29, line 21 page 34, line 23 -page 35, paragraph 1 page 44, line 10-25 page 52, line 29-32	
X	WO 99/48921 A (ORGANON NV ;SPEK PETRUS JOHANNES V D (NL); UNIV LELAND STANFORD JU) 30 September 1999 (1999-09-30)	28,29, 31,33, 34,36, 38,44, 51,53
	abstract claims 1-18	
Ρ,Χ	WO 03/000928 A (PETERSEN MIKKEL WANDAHL; PEDERSEN NINA (DK); MORTENSEN SHILA (DK);) 3 January 2003 (2003-01-03)	1,2,4, 6-9,11, 12,15, 17,23, 28,29, 32-36, 38,44, 51,53
	abstract; claims 131,162	12,21
E .	US 2003/235910 A1 (MONIA BRETT P ET AL) 25 December 2003 (2003-12-25) abstract	1
·	· -/	

INIEHNATIONAL SEAHCH REPORT

T/EP 03/07399

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	1/EP 03/0/399
Calegory •	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
X .	WO 02/29103 A (ALVARES CHRISTOPHER ;HORNE DARCI (US); GENE LOGIC INC (US); PERES) 11 April 2002 (2002-04-11)	1,2,4, 6-12,15, 19,25, 28,29, 31, 33-36, 40,46,
Y	page 76, line 3	51,53 1,2,4, 6-12,15, 19,25, 28,29, 31, 33-36, 40,46, 51,53
U		
X	WO 02/00939 A (DIADEXUS INC ;MACINA ROBERTO A (US); PILLAI RAJESWARI (US)) 3 January 2002 (2002-01-03)	1,2,4-7, 9,11,15, 19,28, 29, 31-36, 40,46, 51,53
	abstract page 35, line 32-35 page 37, last paragraph -page 40, paragraph 1 page 55, last paragraph page 68, paragraph page 82, line 33-35	
P,X	WO 02/084294 A (AXXIMA PHARMACEUTICALS AG; HERGET THOMAS (DE); COTTEN MATTHEW (DE)) 24 October 2002 (2002-10-24) claims 1-29	1,2,4-7, 15,19, 25,51
Y	MOERK H ET AL: "INVERSE MRNA EXPRESSION OF THE SELENOCYSTEINE-CONTAINING PROTEINS GI-GPX AND SEP IN COLORECTAL ADENOMAS COMPARED WITH ADJACENT NORMAL MUCOSA" NUTRITION AND CANCER, LONDON, GB, vol. 37, no. 1, 2000, pages 108-116, XP008014221 ISSN: 0163-5581 abstract	1,2,4, 6-12,15, 19,25, 28,29, 31, 33-36, 40,46, 51,53
	page 108, left-hand column page 109, left-hand column, paragraphs 1,2 page 110, right-hand column, paragraph 3 page 112, right-hand column -page 113, left-hand column page 114, left-hand column, paragraph 2 -right-hand column, paragraph 1	*
	-/	

EP 03/07399

	AND AND SOURCE TO BE BELEVANT	
C.(Continue Calegory *	ction) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/50588 A (INCYTE PHARMA INC ;KLINGLER TOD M (US); LAL PREETI (US); VOLKMUTH) 31 August 2000 (2000-08-31)	1,2,4, 6-12,15, 19,25, 28,29, 31, 33-36, 40,46, 51,53
Y	abstract page 1, line 16-19,23,26 claims 2,,7,,8,,9,,10,,11,,12,,13,,14,M,15,,16 FLORIAN S ET AL: "Cellular and	1,2,4,_
	subcellular localization of gastrointestinal glutathione peroxidase in normal and malignant human intestinal tissue." FREE RADICAL RESEARCH. SWITZERLAND DEC 2001, vol. 35, no. 6, December 2001 (2001-12), pages 655-663, XP009032640 ISSN: 1071-5762 the whole document	6-12,15, 19,25, 28,29, 31, 33-36, 40,46, 51,53
A	KELNER M J ET AL: "Structural organization of the human gastrointestinal glutathione peroxidase (GPX2) promoter and 3'-nontranscribed region: transcriptional response to exogenous redox agents" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 248, no. 1-2, May 2000 (2000-05), pages 109-116, XP004198802 ISSN: 0378-1119 the whole document	1,2,4, 6-12,15, 19,25, 28,29, 31, 33-36, 40,46, 51,53

nation on patent family members

EP 03/07399

Patent document		Publication		Patent family	Publication date
ited in search report		date		member(s)	25-02-1999
NO 9528484	Α	26-10-1995	AU	702522 B2	10-11-1995
			AU	2292595 A	26-10-1995
			CA	2189028 A1	05-02-1997
			EP	0756627 A1 9512167 T	09-12-1997
			JP	2004135670 A	13-05-2004
			JP	9528484 A1	26-10-1995
			MO	5981245 A	09-11-1999
			US US	5981245 A 5981246 A	09-11-1999
		,			00 01 0000
WO 0198350	Α	27-12-2001	AU	7534401 A	02-01 -2 002 27-1 2- 2001
	-		CA	2410864 A1	12-03-2003
			EP	1290029 A2	19-02-2004
			JP	2004505018 T	27-12-2001
			WO	0198350 A2	24-10-2002
			US	2002156035 A1	24-10-2002
WO 0070076	Α	23-11-2000	AU	5022200 A	05-12-2000
HU 00/00/0	••		CA	2373616 A1	23-11-2000
			EP	1183386 A1	06-03-2002
			JP	2002543848 T	24-12-2002
			WO	0070076 A1	23-11-2000
			บร	2003050466 A1	13-03-2003 02-01-2001
			ΑU	5174600 A	21-12-2000
			CA	2382769 A1	20-03-2002
	•		EP	1187908 A1 2003502031 T	21-01-2003
			JP WO	0077173 A1	21-12-2000
					04-07-2002
WO 02051438	Α	04-07 - 2002	MO	02051438 A2 1355666 A2	29-10-2003
			EP US	2004102376 A1	27-05-2004
					18-12-2000
WO 0073801	Α	07-12-2000	ΑŪ	5047800 A 1259812 A2	27-11-2002
			EP	2003518364 T	10-06-2003
			JP	0073801 A2	07-12-2000
			WO	00/3801 AZ	
WO 9948921	Α	30-09-1999	EP	1066324 A1	10-01-2001 12-03-2002
			JP	2002507406 T	30-09-1999
			WO	9948921 A1	
WO 03000928	A	03-01-2003	WO	03000928 A2	03-01-2003
US 200323591	10 A1	25-12-2003	NON	E	
WO 0229103	A	11-04-2002	AU	1131302 A	15-04-2002
MO DSSAIDS	n	11 04 5005	WO	0229103 A2	11-04-2002
			ÜŞ	2002142981 A1	03-10-2002
UO 0000030	Α	03-01-2002	AU	7162101 A	08-01-200
WO 0200939	A	02-01-5005	MO	0200939 A2	03-01-200
			ÜS	2002081640 Al	27-06-200
	A	24-10-2002	CA	2443525 A1	24-10-200
UO 00004004		74-10-500F		02084294 A2	24-10-200
WO 02084294	^		WO	UZU04Z94 AZ	L'1 20 HOV
WO 02084294	^		WO EP	1377833 A2	07-01-200 25-09-200

nation on patent family members

EP 03/07399

Patent document cled in search report	Publication date	Patent family member(s)	Publication date
WO 0050588 A	31-08-2000	AU 3479700 A CA 2361743 A1 EP 1155126 A2 JP 2002536995 A WO 0050588 A2	14-09-2000 31-08-2000 21-11-2001 05-11-2002 31-08-2000